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Abstract
Background: Prevalence of osteoporosis is increasing both in developed and developing countries. Due to rapid
growth in the burden and cost of osteoporosis, worldwide, it seems reasonable to focus on the reduction of
fractures as the main goal of treatment. Although, efficient pharmacological agents are available for the treatment
of osteoporosis, there still remains a need to more specific drugs with less adverse effects.
Main body: This review article provides a brief update on the pathogenesis, presenting current pharmacological
products approved by the US Food and Drug Administration (FDA) or Europe, and also newer therapeutic agents
to treat osteoporosis according to the clinical trial data available at PubMed, UpToDate, International Osteoporosis
Foundation (IOF), and clinical practice guidelines. As well, the effect of combination therapy and recommendations
for future research will be further discussed.
Short conclusion: The use of current antiresorptive and anabolic agents alone or in combinations for the
treatment of osteoporosis entails several limitations. Mainly, their efficacy on non-vertebral fracture reduction is
lower than that observed on vertebral fracture. In addition, they have potential adverse events on long time usage.
Development of newer agents such as cathepsin k inhibitor and strontium ranelate not only have increased the
available options for treating osteoporosis, but also have opened doors of opportunity to improvements in the
effective treatment. However, the high cost of new agents have restricted their usage in selective patients who are
at high risk of fracture or whom failed response to first line treatment options. Thus, personalized medicine should
be considered for future evaluation of genetic risk score and also for environmental exposure assessment. In
addition to permanent attention to early diagnosis of osteoporosis and understanding of the pathophysiology of
osteoporosis for novel approach in drug discovery, there seems a need to more well-designed clinical trials with
larger sample sizes and longer duration on current as well as on newer agents. Also, continuous research on
plant-derived components as the source of discovering new agents, and conducting more clinical trials with combination
of two or more synthetic drugs, plants, or drug-plant for the treatment of osteoporosis are recommended.
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Background
Osteoporosis is one of the common health problems
with a progressive prevalence both in developed and de-
veloping countries [1–3]. The definition of Osteoporosis
based on World Health Organization (WHO) criteria is
reduction in bone mineral density (BMD) of 2.5 standard
deviations or more below that of the mean peak BMD of
young adults when measured by dual-energy x-ray ab-
sorptiometry (DEXA) [4]. This condition is influenced
by different risk factors in terms of sex and age.
In accordance with the recent estimation of Inter-
national Osteoporosis Foundation (IOF) there are 200
million osteoporotic women in the world with an acci-
dent of osteoporotic fracture every 3 seconds [1]. Both
primary and secondary types of osteoporosis are associ-
ated with reduction in bone mass and microarchitecture
that result in bone fragility with a significant increase in
disability, morbidity, and fracture risk [5]. Thus, access
to diagnosis and adequate therapy for osteoporosis is a
main challenge worldwide.
Osteoporosis is more prevalent in women than men;
34% versus 17%, respectively. Usually, osteoporosis is
prevalent in postmenopausal women and is presented as
fractures in hip and spine due to accelerated bone turn-
over secondary to estrogen deficiency. However, vitamin
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D insufficiency and hyperparathyroidism remain as the
main causes of osteoporosis in men and premenopausal
women. By 2050, the worldwide incidence of hip frac-
ture is expected to rise by 240% in women and 310% in
men compared to 1990 involving approximately 1.66
million in 1990 to 6.26 million in 2050 [1]. Total cost
for treating the prevalent osteoporotic-related fractures
in the United States was estimated $19 billion in 2005
that would be tripled by the year 2040 [6, 7]. The annual
hospitalization cost of osteoporotic fractures in US was
shown to be equal or more than annual care costs asso-
ciated with some chronic diseases such as myocardial
infarction (MI), cerebrovascular accident, and breast
cancer in 2011 [8].
A systematic review showed that the costs of osteopor-
osis treatment were not only greater than pre-fracture
costs (as 1.6-6.2 times), but also were more than those
spent for matched controls (2.2-3.5 times) [9].
Thus, due to the rapid growth in burden and cost of
osteoporosis worldwide, it will be reasonable to focus on
reduction of fractures as the main goal of treatment.
WHO has developed an individual patient model known
as FRAX® to calculate individual fracture risk identifying
patients at higher risk of fracture based on clinical risk fac-
tors and femoral neck BMD [10]. In addition to this, it is
important to have a more accurate and comprehensive
look on the pharmacologic therapies of the osteoporosis.
This review article provides an update on the most
current pharmacological products approved by Europe
or the US Food and Drug Administration (FDA) to treat
osteoporosis according to available data at PubMed,
UpToDate, IOF, and clinical practice guidelines.
Pathogenesis
Bone is composed of osteoblasts and osteocytes (bone-
forming cells), osteoclasts (bone-reabsorbing cells) and
osteoid (bone matrix). When the balance between bone
resorption and deposition tips toward excessive resorp-
tion, bone loss occurs as a forerunner of osteoporosis [11].
Osteoporosis is a multifactorial disease which has a
complex pathophysiology potentially caused by genetic,
endocrine disorders, and nutritional factors. Some hor-
mones have been shown to be effective in bone develop-
ment among which parathyroid hormone (PTH),
calcitonin, estrogen and vitamin D are considered the
most important ones [12]. PTH not only can increase
production of the activated form of vitamin D (1, 25-
dihydroxyvitamin D or Calcidiol), but also can increase
calcium absorption through kidneys, bone, and intestine.
In addition, PTH can advance osteoclasts’ activity that
result in further bone resorption. Calcitonin plays roles
in protection of calcium by direct and indirect inhibition
of the PTH effects that result in reduction of calcium re-
sorption from kidneys, calcium uptake from intestine,
and suppression of bone resorption. Calcitonin revers-
ibly blocks osteoclasts’ function by binding to its recep-
tor [12]. Estrogen reduces the rate of bone remodeling
and increases osteoclast
apoptosis through two receptors including estrogen
receptor α (ERα) and estrogen receptor β (ERβ).
Estrogen deficiency has a critical role in the pathogenesis
of osteoporosis due to its association with increased
bone resorption, and impaired bone formation [13].
Bone micro-damages stimulate osteocytes to transmit
resorption signals towards osteoclasts. In an immuno-
logical pathway, receptor activator of NF-κB (RANK) is
expressed as pre-osteoclasts [14]. Function and differen-
tiation of osteoclasts are regulated by RANK/RANK
ligand (RANKL) interaction that can be blocked by oste-
oprotegerin (OPG) (Fig.1). PTH, PTH-related protein
(PTHrP), cytokines, and prostaglandins can increase
osteoclastogenesis by up-regulation of RANKL and
down-regulation of OPG expression [12].
Bone remodeling requires the activities of both
wingless-type and integrase 1 (Wnt) and bone morpho-
genetic protein (BMP) pathways to regulate osteoblast
function (Fig.1). Critical role of Wnt signaling pathway,
and absence of runt-related transcription factor 2
(Runx2) have been shown in regulating osteoblast differ-
entiation and function. Wnt signaling is up-regulated by
interaction of LDL receptor-related protein 5 (LRP5)
and frizzled receptors (Frz), and is down-regulated by
Dickkopf (DKK) as an inhibitor of LRP5 and secreted
frizzled-related protein (SFRP) [13].
Sclerostin acts as an antagonist and blocks both BMP
and Wnt signaling pathways, but canonical β-catenin per-
forms as a synergism with BMP2 and Wnt. Thus, prevent-
ing mutations of gene encoding sclerostin (SOST) can
increase bone formation and bone mass [8]. Some of other
reasons associated with impaired bone formation are age-
related reduction in the capacity of osteoblasts to replicate
and differentiate, local and systemic growth factors defi-
ciencies (IGF-1, TGF- β), prostaglandins (PGE2), leukotri-
enes (arachidonate 15-lipoxygenase that encoded by Alox
15), and leptin deficiency or resistance [13–15]. An inverse
relationship between adipocytes and osteoblasts in the
bone marrow via PPARγ has been shown as a master
regulator of adipogenesis. Also, a close association not
only between bone and insulin sensitivity, but also
between osteoporosis and obesity or diabetes mellitus has
been reported [16, 17].
The key role of oxidative stress, epigenetic, and gut
microbiota in the pathogenesis of osteoporosis is estab-
lished, too. Oxidative stress is an imbalance between the
production of reactive oxygen species (ROS) and antioxi-
dative defense. The effect of oxidative stress on bone is
presented as reduction in bone mass, bone formation,
osteoblast numbers and dysfunction of osteoblasts
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[16–19]. Epigenetic is referred to a stable change of
normal gene expression without altering DNA
sequence in response to various environmental stim-
uli, different pharmacological agents, and nutrients.
All three types of epigenetic markers including DNA
methylation, posttranslational histone modification,
and miRNA are influenced by regulation of gene ex-
pression in bone cells [18, 20]. The effects of gut
microbiota on bone cell have been mediated through
immune systems. Gut microbiota can increase bone
mass and density and can strengthen it by enhancing
the synthesis and absorption of Ca, magnesium, vita-
mins K and B12. Moreover, the synthesis of serotonin
and availability of tryptophan as a serotonin precur-
sor, as well as suppression of osteoclastogenesis is
improved [21].
Management of osteoporosis
Pharmacological agents are used as the typical treatment
of osteoporosis. However, lifestyle modifications through
receiving adequate nutritional supplements (including
calcium intake about 1200 mg daily and vitamin D in-
take in range of 1000-2000 IU daily with higher amount
in some patients), weight bearing activity at least 30 mi-
nutes daily, avoiding or stopping smoking, avoiding
heavy alcohol consumption to ≤2 servings daily, limiting
caffeine intake, and practical and emotional support by
health providers, family and friends have important roles
in maintaining bone health [22–24]. In addition, surgical
treatments such as vertebroplasty and kyphoplasty have
been used for pain relief. It is notable that the main
adverse effect of osteoporosis is the increasing risk of
vertebral fracture. Due to limitations in published stud-
ies assessing the role of these procedures for osteopor-
osis, their benefits have still remained uncertain [22, 23].
Summary of recommended lifestyle modifications and
pharmacological agents for osteoporosis are shown in
Table 1.
Calcium and vitamin D supplementation
In some countries calcitriol and alfa-calcidol have been
used as synthetic analogues of vitamin D for the treat-
ment of osteoporosis. A meta-analysis showed that vita-
min D supplementation alone cannot reduce fracture
risk. However, the results of another meta-analysis
revealed a fracture risk reduction at vertebral and non-
vertebral sites [25, 26]. However, the beneficial effect of
calcitriol was reported for prevention of bone loss in
osteoporosis after glucocorticoid therapy or after trans-
plantation of solid organ or stem cell [27]. The main
adverse effects of vitamin D derivatives are increasing
the serum and urine level of calcium. The beneficial
Fig. 1 A brief schematic view of pathophysiology of osteoporosis and influence of some drugs on bone health. Legend: PTH: parathyroid
hormone; PGE2: prostaglandin E2; IL-11: interleukin-11; OPG: osteoprotegerin; OCIF: osteoclastogenesis inhibitory factor; RANKL: receptor activator
of nuclear factor κB ligand; NF-κB: nuclear factor κB; JNK: c-Jun N-terminal kinases; OCs: osteoclasts; Wnt: wingless and Int proteins; LRP5/6:
LDL-receptor related protein 5/6; IGF-1: Insulin like growth factor-1; L-C: L-carnitine; OBs: osteoblasts
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effects of adequate intake of calcium (Ca) and vitamin D
on rate of bone loss and fracture risk has been shown in
a study [28]. Some of meta-analysis studies reported
0.81-0.87 relative risk reduction for hip fracture (13-19%
reduction) by combination of Ca with vitamin D [29,
30]. Generally, recommended daily intake of Ca and
vitamin D in postmenopausal osteoporotic women is
1200 mg (total intake by diet and supplements) and 800
international units (IU), respectively. These amounts can
change to 1000 mg (total intake by diet and supple-
ments) and 600 IU, respectively, in premenopausal
osteoporotic women and men [31].
Pharmacological agents for treatment of osteoporosis
Pharmacological agents are classified into two groups,
antiresorptive and anabolic agents. The main mechanism
of action of antiresorptive agents is reduction of bone
resorption through inhibiting the activity of osteoclasts.
Drugs of this class include calcitonin, bisphosphonates,
estrogen, selective estrogen-receptor modulators, and
denosumab. Administration of anabolic agents can result
in new bone formation through stimulating the function
of osteoblasts.
These medications may have some beneficial effects
on extra-skeleton tissues and organs but by considering
the most part of the burden of osteoporosis which is re-
lated to fractures especially hip fracture; the current
approach to treatment of osteoporosis is focused on
patient’s BMD and fracture risk. The beneficial effects of
the pharmacological agents were presented in Table 2.
Approved FDA/Europe antiresorptive drugs
Bisphosphonates (BPs) BPs are recommended as the
first-line medications for treatment of osteoporosis.
Their effects on bone cells are most notable through
inactivating osteoclastic bone resorption and accelerat-
ing apoptosis of osteoclasts. BPs can increase BMD, and
decrease fracture risk. Drugs of this group include alen-
dronate (Fosamax®), risendronate (Actonel®), ibandronate
(Boniva®), zoledronic acid (Reclast®), clodronate
(Bonefos®, Clasteon®), minodronate (Onobis®), pamidro-
nate (Aredia®), etidronate (Didronel®), and tiludronate
(Skelid®) which are different in terms of structure,
potency, and affinity to bone. In addition, some of them
such as etidronate and pamidronate are available in the
US but not approved for prevention or treatment of
osteoporosis [22].
Alendronate and risendronate are the most commonly
used BPs worldwide. Alendronate not only has high af-
finity to bone, but also its effects have longer duration.
Initiation of protective anti-fracture effect of alendronate
is varied based on bone sites; 12, 18, or up to 24 months
after treatment for vertebral bone, hip, and non-
vertebral bone, respectively. Risendronate has a low
affinity to bone, and its protective anti-fracture effect is
started at least 6 months after treatment for vertebral
and non-vertebral bones [32].
However, an increase in spine BMD rather than
decrease in fracture risk was shown for zoledronic acid
[33]. Clodronate is a weak BPs with beneficial effects on
spine and hip BMD as well as vertebral and non-
vertebral fracture risk in clinical trials. Its usage for
osteoporosis has been approved in Europe [22]. A
network meta-analysis compared the short term efficacy
of different BPs including alendronate, clodronate,
ibandronate, minodronate, pamidronate, risedronate,
zoledronic acid, etidronate, and tiludronate in preven-
tion of fractures in primary osteoporosis. The most
effective BPs in the prevention of fracture at any sites
was zoledronic acid, but alendronate or zoledronic acid
Table 1 Summary of treatment modalities for osteoporosis
Treatment modalities Drug class Medications
Lifestyle modifications Nutritional supplements
Physical activity
Smoking cessation
Limited alcohol & caffeine
consumption
Calcium & Vitamin D
Pharmacological agents (antiresorptive drugs) BPs Alendronate, Risedronate, Ibandronate, Zoledronic acid,
Clodronate, Minodronate, Pamidronate, Etidronate, Tiludronate
RANKL antibody Denosumab
Estrogen replacement Estrogen conjugate
SERMs Raloxifene, Tamoxifene, Lasofoxifene, Bazedoxifene, Arzoxifene
Calcitonin Calcitonin
Cathepsin k inhibitors Odanacatib, Balicatib, ONO-5334
Strontium ranelate Strontium
Pharmacological agents (anabolic drugs) PTH peptides
Anti-sclerostin antibodies
Teriparatide, PTH 1-84
Romosozumb, Blosozumab, BPS804
Legend: BPs Bisphosphonates, SERMs selective estrogen receptor modulator
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Table 2 Summary of characteristics of pharmacological agents for treating osteoporosis in clinical trials’ studies
Drugs class Medication Route of administration Evidences of main effect Ref.
Increase in BMD Decrease in fracture risk
FDA/EU Approved
Antiresorptive BPs
Alendronate PO Spine 6.2%, hip 4.1%,
LS 5.4%, FN 1.6%,
Vertebral 47%, hip 51%,
non-vertebral 16%
[1, 33, 37]
Risedronate PO Trochanter 3.3% Vertebral 36%,
non-vertebral 27%,
hip 40%
[1, 37]
Ibandronate PO/IV Nearly 6% for LS & hip Vertebral 50%,
Non-vertebral 30-40%
[1, 22, 34–37]
Zoledronic acid IV LS 3.2%, FN 24% Vertebral 70%,
non-vertebral 25%
(including hip 40%)
[37, 38]
Clodronate PO/IM/IV LS 3.7%, hip 1.3% Vertebral 43%,
non-vertebral 33%
[22]
Denosumab SC LS 9.2-18.4%, hip 4-8.3% Vertebral 68%, hip 40%,
non-vertebral 20%
[45, 46]
Estrogen Replacement
(ERT, HRT)
PO LS 7.6%, hip 4.5% ERT: Vertebral 38%, hip
39%
HRT: Vertebral 35%,
hip 33%, wrist 29%
[22, 52, 53]
SERMs
Raloxifene PO LS 1.8%, hip 2.1% Vertebral 35-43%,
non-vertebral 10%
[22, 48, 57]
Bazedoxifene PO LS 2.2-2.7%, hip
(-1.15)-1.5%
(dose dependent)
Vertebral 37-42%,
non-vertebral no effect
to 44-50% reduction
[56, 59, 60]
Bazedoxifene+
conjugated estrogen
PO LS 0.5-1.6%, hip 0.5-1.5% NA [62]
Tamoxifene PO LS 1.2% Overall 32% (hip 32%,
spine 25%, radius 31%)
[63]
Lasofoxifene PO LS 1.8-3.0%, hip 1.3-1.9% (dose dependent)
Vertebral 31-42%,
non-vertebral 22-24%,
no effect on hip fracture
[64, 66]
Arzoxifene PO LS 2.75-2.9%, hip 1.53% Vertebral 41%, no reduced
non-vertebral
[67, 68]
Calcitonin Nasal spray/SC/IM LS 1-1.5% Vertebral 60% [55]
Anabolic agents PTH peptides
Teriparatide SC Spine 8.6-13%, FN 3.5-6% Vertebral 65-69%,
non-vertebral 53%
[6, 55, 72, 73]
PTH 1-84 SC LS 6.9%, FN 2.5% Vertebral 60% [11, 73]
Newer Agents (awaiting FDA/EU approval)
Antiresorptive Cathepsin k inhibitors
Odanacatib PO Spine 11.9%, total hip 8.5%,
FN 9.8%
Hip 47%, non-vertebral
23%, clinical vertebral 72%
[71, 76]
ONO-5334 PO Spine 3.7-5.1%, total hip 3%,
FN 2.6%
NA [78]
Strontium PO Dose dependent: LS 2.39-5.44%,
FN 2.52-8.25%, total hip 1.02-8.25%
Vertebral 37-40%,
non-vertebral
13%, hip 5%
[81, 82]
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revealed the highest effectiveness solely in preventing
hip fracture [34]. Overall, the choice of BPs depends on
the tolerance, cost, and medical history of patients. The
influential effect of BPs in BMD and fracture risk varies
in different studies. Some of the reasons are related to
the age and sex of studied population, pre- or post-
menopausal status, history of previous fracture, the type
of the study (observational or clinical trial), and their
comparison with placebo or other pharmacological treat-
ments of osteoporosis [1, 22, 34–39]. A summary of the
evidence-based data are shown in Table 2.
According to the American Association of Clinical
Endocrinologists (AACE), response to treatment (not
only with BPs but also with other pharmacological
agents for treating osteoporosis) can be monitored by
serial assessment of BMD (hip and lumbosacral) every
one-two years after initiating BPs therapy until change
in BMD become stable, and then repeats every two years
or at less frequent intervals [23]. In some situations that
absorption or efficacy of the drugs may be negatively af-
fected, measuring bone turnover markers is recom-
mended as an additional option; urinary N-telopeptide
(NTX) and serum carboxy-terminal collagen crosslink
(CTX) before and 3-6 months after initiating BPs and
other antiresorptive agents. The extension of
HORIZON-PFT trial and the Fracture Intervention Trial
Long-Term Extension (FLEX) study revealed the highest
beneficial effects of zelodronate after 3 years and alen-
dronate after 5 years with regard to the fact that BMD
and fracture outcomes were retained 6-9 years or
10 years after interrupting treatment with zelodronate or
alendronate, respectively [40–42]. Thus, BPs therapy can
be recommended beyond 5 years for patients at high risk
of fracture. If the clinician decides to discontinue the
treatment, it is necessary to assess BMD annually or bi-
annually, concomitant to the measurement of bone
Table 2 Summary of characteristics of pharmacological agents for treating osteoporosis in clinical trials’ studies (Continued)
Anabolic agents Anti-sclerostin
antibodies
Romosozumab SC Dose dependent: LS 5.4-11.3%,
total hip 4.1%, FN 3.7%
NA [84]
Blosozumab SC/IV Dose dependent: spine 8.4-17.0%,
total hip 2.1-6.3%, FN 2.7-6.3%
NA [85]
Combination therapy
Antiresorptive
and anabolic
agents
BPs + PTH
Alendronate +
Teriparatide
PO/SC LS 14.8% vs. 18.1% by PTH/
7.9% by BPs, total hip without
differences
NA [73]
Risedronate +
Teriparatide
PO/SC Total hip 3.9% vs. 0.3% by PTH/ 0.8%
by BPs, FN 8.4% vs. 3.9% by PTH/
0.5% by BPs
NA [73, 93]
Zoledronic acid +
Teriparatide
IV/SC LS 7.5% vs. 7.0% by PTH/ 4.4% by BPs,
total hip 2.3% vs. 1.1% by PTH / 2.2%
by BPs
NA [93]
Denosumab +
Teriparatide
SC/SC LS 9.1% vs. 6.2% by PTH/ 5.5% by
denosumab, total hip 4.9% vs. 0.7%
by PTH/ 2.5% by denosumab, FN 4.2%
vs. 0.8% by PTH/ 2.1% by denosumab
NA [94]
SERMs+ Teriparatide
Raloxifene +
Teriparatide
PO/SC LS 6.2% vs. 5.2% by PTH, total hip 2.3%
vs. 0.8% by PTH, FN 2.2% vs. 1.0%
by PTH
NA [57]
Antiresorptives BPs+ HRT
Etidronate +
Estrogen
PO/PO LS 10.4% vs.7.0% by HRT, hip 7.0%
vs. 4.8% by HRT
NA [95]
Alendronate +
HRT
PO/PO LS 10.1% vs. 4.0% by HRT, FN 4.0%
vs. 2.0% by HRT
NA [35, 96]
Risedronate +
HRT
PO/PO LS 5.2% vs. 4.6% by HRT, FN 2.7%
vs. 1.8% by HRT
NA [35]
BPs+ SERMs
Alendronate +
Raloxifene
PO/PO LS 5.3% vs. 4.3% by BPs/ 2.1% by
raloxifene, FN 3.7% vs. 2.7% by BPs/
1.7% by raloxifene,
NA [57, 95]
Legend: BPs Bisphosphonates, FDA Food and Drug Administration, EU Europe, PO oral route, IV intravenous, SC subcutaneous, IM intramuscular, BMD bone mineral
density, LS lumbar spine, FN femoral neck, GI gastrointestinal, HRT hormone replacement therapy, SERMs selective estrogen receptor modulators, AF arterial
fibrillation, NA no evidence available
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markers and evaluating their changes. Hypocalcaemia,
vitamin D deficiency, and renal dysfunction should be
evaluated prior to initiating BPs through measuring
serum level of Ca, 25-hydroxyvitamin D, and creatinine,
and also the comorbidities that can influence on BPs
usage and absorption should be assessed [35]. Some of
these comorbidities are history of esophageal disorders
such as achalasia that should be assessed before initiat-
ing oral BPs [35]. For achieving good efficacy of BPs, it
is necessary to maintain optimal levels of calcium and
vitamin D by adequate intake and/or supplementation.
The most commonly reported adverse effects for oral
BPs are gastrointestinal (GI) disturbances especially dys-
pepsia and esophagitis. So, oral BPs should be taken with
an 8-ounce glass of water, upright for at least 30 minutes,
and avoidance of sucking or chewing tablets. Flu-like
symptoms was shown by taking large doses of oral or
intravenous (IV) modes of BPs that can often be man-
aged with acetaminophen. Other reported adverse effects
are rare and include jaw osteonecrosis, atypical subtro-
chanteric femoral fractures, arterial fibrillation, and
acute renal failure [35, 43–45]. Despite case reports of a
serious adverse reaction by BPs [41], they have remained
as the front line treatment for osteoporosis, at this time,
based on risk-benefit ratio for using BPs especially
reduction of the fracture risk [23, 35].
Denosumab
Denosumab (Prolia®) is a human monoclonal RANKL
antibody that results in osteoclast inactivation, apoptosis,
and reduction in osteoclasts’ differentiation by blocking
the binding of RANKL to RANK. In addition a reduc-
tion of bone resorption as well as more than 80%
decrease in serum level of CTX-1 has been reported [1].
Although it is not as the first-line pharmacological treat-
ment of osteoporosis, but can be initiated as a first-line
choice for treatment of osteoporosis in certain patients
who are intolerant to oral BPs or have renal failure [46].
The “Fracture REduction Evaluation of Denosumab in
Osteoporosis every 6 Months” (FREEDOM) trial showed
the efficacy of denosumab on fracture-risk reduction at
different skeletal sites among osteoporotic women [47].
Moreover, in patients at high fracture risk its beneficial
effects were shown in older men under androgen-
deprivation therapy for prostate cancer, and women who
receive adjuvant aromatase inhibitor for breast cancer.
Generally, it is not recommended to be used in premen-
opausal women or children and for prevention of osteo-
porosis. Its combination with other pharmacological
agents for osteoporosis is not suggested. Similar to BPs,
hypocalcaemia and vitamin D deficiency should be man-
aged before starting treatment, and adequate Ca and
vitamin D should be administered during treatment with
denosumab. It was reported that the beneficial effects of
denosumab on bone initiate after one month and main-
tain at least 2 years in different clinical trials [23, 48, 49].
Monitoring of response to treatment with BMD is simi-
lar to monitoring of other pharmacological agents for
osteoporosis that BMD evaluation is recommended
2 years after treatment. Due to the expression of RANK
and RANKL on T lymphocytes, B cells, and dendrites’
cells, an increase in the risk of infection by denosumab
or its combination with other biologic agents is
expected. Although there is no sufficient supportive data
for infection or cancer in clinical trials, longitudinal
studies are recommended to reveal the effect of long-
term disruption in the receptor sites of RANK on
immune system [48]. However, due to more frequent
reports of serious infection and skin reaction with deno-
sumab compared than placebo, patients should be
informed to use appropriate drugs if develop signs of in-
fection or skin reaction. Denosumab was not only well
tolerated in osteoporosis clinical trials, but also no
account of jaw osteonecrosis, arterial fibrillation, and
symptomatic hypocalcaemia is reported, yet. Of the most
commonly reported adverse effects were musculoskeletal
pain, hypercholesterolemia, and cystitis [46].
Estrogen replacement
Due to the important role of estrogen deficiency on
bone loss during menopause, it is suggested that use of
estrogen replacement therapy (ERT) or estrogen-
progestin (hormone) replacement therapy (HRT) alone
is effective for prevention of osteoporosis in postmeno-
pausal women [50]. Although the main effect of estrogen
on bone health is reducing bone resorption, an anabolic
effect was shown, too [51]. The Women’s Health
Initiative (WHI) and the Postmenopausal Estrogen/Pro-
gestin Intervention (PEPI) trial showed beneficial effects
of either ERT or HRT at all skeletal sites concomitant
with some adverse effects in long term usage [52–54].
Tibolone is an estrogen-progestin combination that is
available outside of the US. It is formulated as tablet and
is commercialized under different brand names around
the world, for example as Boltin® or Tibocina® in Spain
and Xyvion® in Australia. Tibolone is used for prevention
of osteoporosis and treatment of vasomotor symptoms
of menopause. The Long-term Intervention on Fractures
with Tibolone (LIFT) study conducted in post-
menopausal women was shown its beneficial effects on
reduction of fracture risk at vertebral (45%) and at non-
vertebral (26%) sites [55]. It was shown that HRT can
increase the risk of venous thromboembolic disorders,
breast cancer, cardiac event and stroke, while ERT could
enhance the risk of venous thromboembolic disorders,
stroke, and endometrial cancer [23, 56]. Thus, estrogen
replacement is recommended at the lowest effective dose
and just for a short period. Moreover, HRT or ERT are
Tabatabaei-Malazy et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:2 Page 7 of 16
not recommended as the first-line preventive treatment
of osteoporosis. Beneficial effects of estrogen therapy on
BMD will be decreased as nearly 5% during the first year
after stopping treatment [22, 23].
Selective estrogen receptor modulators (SERMs)
Due to the adverse effects of estrogen in extra-skeletal
organs, SERMs has been considered for treating osteo-
porosis in both sexes. SERMs contain nonsteroidal syn-
thetic compounds with similar effects of estrogen on
bone and cardiovascular system without any adverse ef-
fects of estrogen on breast and endometrium. This
group includes raloxifene (Evsita®), tamoxifene (Solta-
mox®), lasofoxifene (Fablyn®), and bazedoxifene (Viviant®,
Conbriza®).
Raloxifene is the first produced drug of this class. Its
beneficial effects on bone were shown in the Multiple
Outcomes of Raloxifene Evaluation (MORE) trial and
the Raloxifene Use for the Heart (RUTH) study as re-
duction in vertebral fracture risk without any significant
effect on non-vertebral fracture risk [57–59]. The safety
and efficacy of raloxifene on BMD can be extended for
eight years according to clinical trials. Although some
clinicians are continuing its usage after 8 years, no re-
sidual benefit was shown on BMD after stopping usage
[57]. Due to reduction of BMD and enhancement of
bone turnover associated with raloxifene in premeno-
pausal women, it is not recommended in this popula-
tion. Raloxifene can decrease the risk of breast cancer,
but can increase the rates of stroke, thromboembolism,
leg cramp, and postmenopausal vasomotor symptoms
[49]. So, new drug discovery efforts should be focused
on new versions of SERMs with maximum beneficial ef-
fects on bone and the least adverse effects.
Bazedoxifene that is available in Europe and Japan
have similar effects to raloxifene in osteoporosis [60, 61]
but its long term safety or its impact on the risk of
breast cancer is not yet determined. Although it is ap-
proved by Europe, is not approved yet by FDA at the
time being. One formulation of bazedoxifene is its com-
bination with conjugated estrogen (Duavee®) that can be
used for treatment of osteoporosis and reduction of
postmenopausal hot flashes [62]. Its common adverse ef-
fects are muscle cramps, GI disturbance, dizziness and
neck pain. Other adverse effects are increased risk of
stroke and thromboembolic diseases. Overall, the long
term safety and preventive effect of Duavee on breast or
ovarian cancers are unknown.
Tamoxifen as another drug from SERMs class has shown
BMD reduction in premenopausal women by suppressing
estrogen action on bone which is in contrast to its effect on
postmenopausal women. But its impact on prevention or
treatment of breast cancer in premenopausal is supportive.
Thus, bone health can be monitored by evaluating BMD in
this population [57, 63, 64]. Previous studies have reported
that tamoxifen increases or stabilizes bone density, and de-
creases fracture rate in postmenopausal patients; however,
no persisting benefit in terms of BMD is reported after
2 years of tamoxifen consumption following aromatase in-
hibitors treatment such as latrozole in postmenopausal
women with estrogen receptor-positive breast cancer.
Stopping tamoxifen would result in a rapid fall in estrogen
levels induced by the aromatase inhibitors and may cause
an accelerated BMD loss following the switch [65].
Due to the positive association between usage of
tamoxifen and risk of endometrial hyperplasia or cancer,
and vaginal bleeding, it should not be considered as the
first-line therapeutic option of SERMs class for treating
osteoporosis [57].
Lasofoxifene has shown protective effects on bone un-
like its effect on breast and uterine. In different clinical
studies conducted in postmenopausal osteoporotic
women, some dose dependent beneficial and adverse
effects of lasofoxifene at the dose of 0.25, 0.5, or 1.0 mg/
once daily were shown versus placebo [66, 67]. Lasofoxi-
fene at the dose of 0.5 mg/daily was associated with
reduction in vertebral and non-vertebral fracture risk,
estrogen positive breast cancer, cardiovascular diseases
(CVD), stroke, and increasing risk of thromboembolic
events compared with the dose of 0.25 mg/daily [67]. It
is approved by Europe but not approved by FDA.
Arzoxifene (LY353381) as a long acting raloxifene and
ospemifene (Ophena®) that is structurally tamoxifene-
like are new versions of SERMs with beneficial effects
on bone such as increased BMD, decreased bone turn-
over, and fracture risk [49, 64, 68]. It should be noticed
that clinical studies with ospemifene and arzoxifene are
proceeding that are not approved by FDA, yet.
Generally, BPs or raloxifene are suggested as first-line
choices for prevention of osteoporosis in postmeno-
pausal women, pointing out that BPs are recommended
over SERMs for treatment of osteoporosis. One should
consider that the non-skeletal effects of SERMs have
important role in selection of patients to use them.
Raloxifene is contraindicated for prevention or treatment
of osteoporosis in premenopausal women. BMD monitor-
ing is required in the population taking tamoxifen [57].
Calcitonin
Calcitonin (Fortical®, Miacalcin®, Calcimar®) as a natural
32-amino-acid peptide is secreted by C-cells of the thy-
roid. It is considered as a second-line therapy for osteo-
porosis in settings where first-line drugs have failed to
response or patients are found intolerable. Calcitonin is
administered in two dosage forms; injectable and nasal
spray that bioavailability of nasal calcitonin is about 1/4
that of its intramuscular route [69]. Usually, human cal-
citonin and salmon calcitonin have studied in clinical
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trials. Salmon calcitonin is used widely than human
calcitonin due to its high affinity as 40 times more than
human calcitonin for human calcitonin receptor.
Calcitonin inhibits bone resorption through increasing
osteoblast activity that results in reduction in vertebral
fractures with a mild increase in spine BMD. Data on
the effect of calcitonin on BMD of other skeletal sites
are conflicting. However, its beneficial effects on bone
were shown in both sexes by using both human and sal-
mon calcitonin, both subcutaneous and intranasal routes
[11, 69]. There are not sufficient data on its effectiveness
in women who are in the early postmenopausal years.
Thus, it is recommended as a second-line treatment for
women at more than 5 years after menopause. Due to
some reasons, including lesser effectiveness of calcitonin
than BPs, increased risk of cancer by its long-term
usage, and less availability compared to BPs, calcitonin is
typically not used for treating osteoporosis unless to re-
lief acute pain (onset <10 days) secondary to osteopor-
otic fracture. In contrast, calcitonin is not effective for
chronic pain (more than 3 months). The adverse effects
include nausea, vomiting, flushing, allergic reactions,
hypocalcaemia, nasal adverse reactions, calcitonin’ anti-
bodies formation, and prostate cancer. In required situa-
tions, one should cease its use in less than 6 months. In
addition, after relieving from acute pain of fracture,
calcitonin should be quickly switched to other pharma-
cological treatments of osteoporosis [69]. Calcitonin has
withdrawn from the market in Europe and Canada. Al-
though it is available in the US for treating osteoporosis,
FDA Advisory Committee has not recommended it, yet
[55]. In 2013, FDA advisory panels have recommended
that marketing of calcitonin salmon for the treatment of
osteoporosis in women greater than 5 years after meno-
pause should be stopped. This is while in 2012, the
European Medicines Agency had recommended that cal-
citonin salmon should not be used to treat osteoporosis
after determining that the risk of developing cancer was
2.4% higher in patients using the nasal spray compared
with in those who took placebo [70].
Approved FDA/Europe anabolic agents
PTH Teriparatide (recombinant human parathyroid 1-
34) (Forteo®) and intact molecule (amino acids 1-84) are
peptides of PTH that have anabolic effects on bone mass
and skeletal architecture by intermittent administration.
Once daily subcutaneous administration of both agents
have been shown to promote bone formation through
activating osteoblasts’ function by binding to PTH/
PTHrP type 1 receptor and stimulation of Wnt signaling
pathway which resulted in increasing BMD and reducing
fracture risk [71]. Both analogues can reduce vertebral
fracture risk, but teriparatide can reduce non-vertebral
fracture risk concomitant with reduced BMD in forearm
[72]. A meta-analysis study showed a reduction in the
risk of back pain due to reduced occurrence of new
painful vertebral fractures [73]. Abaloparatide (BA058®)
is a synthetic peptide analog of PTHrP that is in the
process of applying to be approved in FDA and Europe.
An increase by 6.7% was shown in a phase II clinical
trial at lumbar spine BMD without significant difference
from teriparatide and 2.6% increase at total hip BMD by
abaloparatide with a significant difference from teripara-
tide. A phase III clinical trial concluded the reduction of
major osteoporotic fracture risk by applying both formu-
lations but significantly marked the administration of
abaloparatide [74]. The beneficial effect of abaloparatide
was shown on wrist fracture, too. So, it seems that the
abaloparatide is superior to teriparatide in terms of frac-
ture prevention [74]. PTH analogous are not recom-
mended as first-line drug given to the cost of PTH
analogous, subcutaneous (SC) route of administration,
and the availability of other pharmacological agents for
treating osteoporosis [73]. On the other word, these
drugs are suitable for patients at high risk of fracture, se-
vere osteoporosis (BMD < -3.0 T score), unsatisfactory
response to anti-resorptive agents or unable to tolerate
BPs, and patients with glucocorticoid-induced osteopor-
osis [6]. Its common adverse effects include dizziness,
headache, nausea, and leg cramp [75]. Osteogenic sar-
coma was shown followed by treatment with teriparatide
in a dose and duration dependent pattern in experimen-
tal studies; however, it was not found in patients who
used very trivial dosages of teriparatide [22]. Its use is
contraindicated in patients with Paget, past bone irradi-
ation therapy, hypercalcemia, hyperparathyroidism, bone
metastasis, unexplained high level of alkaline phosphat-
ase, and severe renal failure. It should be used with cau-
tion in patients with past or present history of kidney
stones. Before the initiation of PTH therapy, BMD (if
not assessed during two years ago), serum level of Ca,
phosphorus, creatinine, alkaline phosphatase, albumin,
25-hydroxy vitamin D, and 24-hour urine excretion of
Ca and creatinine should be evaluated. Vitamin D defi-
ciency should be managed with vitamin D pretreatment.
In addition, it is recommended to intake 1500 mg daily
Ca and 800 IU daily vitamin D while receiving PTH.
Transient orthostatic hypotension was reported in some
cases. Overall, teriparatide treatment is limited to 2 years
in a patient's lifetime. Usually, monitoring of BMD is not
recommended during the first to the second year of
PTH therapy, but renal function and serum Ca measure-
ments should be performed at least once during treat-
ment with PTH [73]. The beneficial effect of PTH on
fracture risk has persisted for at least 18 months (up to
30 months for teriparatide) after stopping treatment
which can be avoided by taking an antiresorptive agent
such as BPs [55].
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New agents
The main goal of treating osteoporosis is based on
marked increase in BMD and fracture free-period. Des-
pite that current medications have effectively reduced
fracture risk and increased BMD, understanding the tar-
gets of signaling pathways have helped to discovery of
newer agents. Currently progression in development of
newer agents such as cathepsin k inhibitor, strontium
ranelate, AMG785, and AMG167 not only have
increased the available options for treating osteoporosis,
but also have opened doors of opportunity to improve-
ments in the effective treatment.
Cathepsin k inhibitor
Cathepsin k is a cysteine protease that is expressed by
osteoclasts. Cathepsin k can degrade matrix proteins and
type I collagen that results in bone resorption. Cathepsin
k inhibitors such as odanacatib (MK-0822, MK-822),
balicatib (AAE581), and ONO-5334 can reduce bone re-
sorption, and bone formation. Beneficial effect of odana-
catib in the interim analysis of a phase III clinical trial
(The Long-term Odanacatib Fracture Trial, LOFT) with
postmenopausal women has shown moderate reduction
in bone resorption (50%), lesser decrease in bone forma-
tion (30%) concomitant with beneficial effect on hip and
spine BMD. The beneficial effects of odanacatib as a se-
lective cathepsin k inhibitor on BMD were reported to
be dose dependent and persist up to 5 years by treat-
ment. In addition, its fracture risk reduction effect is
comparable with the effects of BPs and denosumab on
similar bone sites [76]. Results of a number of phase II
clinical trials have shown its beneficial effect on bone re-
sorption markers in a dose dependent manner in both
sexes [77, 78]. A phase II clinical trial by AAE581 on site
of ClinicalTrials.gov was found; however, the authors
have not revealed any report of their study. Phase II
OCEAN clinical trial demonstrated that ONO-5334 can
decrease bone resorption similar to alendronate, with lit-
tle or no change in bone formation and can increase
BMD of lumbar spine, total hip and femoral neck com-
parable to alendronate [78]. However, its safety is not yet
identified. All of these effects are reversible after stop-
ping treatment. So, another medication should be added
after taking off cathepsin k inhibitors to prevent loss of
their beneficial effects on bone. Plaque-like skin thicken-
ing (morphea) that was one of the main adverse effects
of early cathepsin k inhibitors (balicatib), was reported
in 0.1% of users with odanacatib, ONO-5334 and other
under development cathepsin k inhibitors (similar to
placebo group). Some of the reported adverse effects of
odanacatib versus placebo are trivial increase in the risk
of stroke (1.4% vs. 1.1%), arterial fibrillation (1.1% vs.
1.0%), and atypical fractures (0.1% vs. 0%). However,
these types of drugs are still under development and
await approval [71, 79].
Strontium ranelate
Strontium ranelate (Protelos®) is an antiresorptive agent ap-
proved in Europe for treatment of severe osteoporosis in
mobile postmenopausal women at high risk of vertebral
and hip fractures who cannot use or tolerate other pharma-
cological agents. In addition, it is recommended for use in
Europe to treat osteoporosis in men at high risk of fracture.
Although its mechanism of action is unclear, modest antire-
sorptive effect and little beneficial effect on bone formation
are noted. Inhibition of osteoclasts’ function as well as pro-
motion of osteoblasts’ activity through calcium sensing re-
ceptor (CaSR) by strontium resulted in increasing BMD
and decreasing fracture risk [80–82]. In addition, its effects
on osteoblast differentiation and proliferation have been
shown. Since the replacement of Ca ions in the hydroxy-
apatite crystals by strontium salt leads to a larger apparent
increase in BMD, one should consider to include correction
factors in BMD data of the strontium users to make up the
effects of this artifact which may influence DXA results.
The magnitude of changes observed in BMD followed by
strontium therapy is not suggestive of a greater reduction
in fracture risk. On the other word, a greater BMD doesn’t
imply a larger reduction in fracture risk [27]. The more
common reported adverse effects are cardiovascular events,
venous thromboembolism, myocardial infarction, GI dis-
comfort, and signs and symptoms of nervous system such
as headache, seizure, memory loss, but rarely reported
adverse effect is allergic reactions such as drug rash with
eosinophilia and systemic symptoms (DRESS syndrome)
[55, 77, 81]. Continuation of treatment with strontium
should be stopped when hypertension, angina, or DRESS
syndrome develop. In 2013, the European Medicines
Agency’s (EMA's) Committee for Medicinal Products for
Human Use (CHMP) recommended a restriction in the use
of the osteoporosis medicine Protelos/ Osseor (strontium
ranelate), following an assessment of data showing an in-
creased risk of serious heart attack, with no observed
increase in mortality risk. The CHMP recommended that
Protelos should only be used to treat severe osteoporosis in
postmenopausal women or in men at high risk of fracture.
Additional measures, including restrictions in patients with
heart or circulatory problems, were also recommended to
minimize the heart risks of the medicine [83].
Anti-sclerostin antibodies
Anti-sclerostin monoclonal humanized antibodies such as
romosozumb (AMG785), blosozumab (AMG167), and
BPS804 are osteocytes-derived Wnt signaling antagonists.
Stress can stimulate osteoblasts to secret osteocytes as a
mechanical signaling that results in decreasing the expres-
sion of sclerostin. On the other word, sclerostin prevents
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bone formation through suppressing the binding of LRP
5/6 to Frz on osteoblasts which decrease differentiation,
function and survival of osteoblasts. Increasing bone mass
at spine and hips in clinical trials was shown concomitant
with increasing in bone formation markers and decreasing
in bone resorption markers by romosozumb and blosozu-
mab [84, 85]. Variations in both of these significant bone
markers’ will return to baseline levels (in a dose dependent
manner) after 12 months which confirms the existence of
other pathways independent of sclerostin for decreasing
mechanical strain in the skeleton. Another reason of this
event may be related to reduction of osteoblast progeni-
tors or the compensatory activation of other signaling
molecules such as DKK that reduce bone formation [86].
In addition, a positive association between bone mass and
circulating level of sclerostin was shown in healthy men
and women in contrast to the observed results in patients
with bone disorders. The reason of this association may
be related to high production of osteocytes as the main
source of sclerostin secondary to higher bone mass [87].
So, more studies are needed to definite optimal doses, ap-
propriate duration of treatment, and anti-fracture efficacy.
The beneficial effects of anti-sclerostin antibodies were
shown in animal models of other conditions resulted in
decreasing BMD such as colitis, rheumatoid arthritis,
osteoarthritis, osteogenesis imperfecta, and bone compli-
cations of type 2 diabetes mellitus [88]. The most fre-
quently reported adverse effects are elevated liver
enzymes after first dose that is normalized nearly after one
month, and injection site reactions. There are rarely re-
ported anti-blosozumab antibodies that decline with stop-
ping treatment. In addition, just one case of nonspecific
hepatitis after taking 10 mg/kg of romosozumab was
reported which improved after 26 days [71]. By consider-
ing the hypothesis that activation of Wnt signaling can
increase cardiovascular events or intracranial pressure due
to unrestricted bone formation, and also the relation
between sclerostin and some tumors such as colon cancer,
long-term safety of these drugs are uncertain.
Other therapies
There are additional therapies for postmenopausal
osteoporotic women such as vitamin K, folic acid, vita-
min B12 supplementations, androgens, and fluoride that
are used in some countries, but are not recommended
for routine use [27, 89]. However, there are other agents
that have been shown to influence bone health through
antiresorptive or anabolic mechanism, but are under in-
vestigations. The RGD sequence and human ß3 integrin
have been reported as important targets for antiresorp-
tive gene therapy. As a result, some studies have sug-
gested the use of mesenchymal stem cells, which are
osteoblast precursor cells, to carry the therapeutic gene.
OPG, BMP and PTH have been reported as the most
promising molecules for osteoporosis treatment, but not
many new molecules have been studied as possible
targets in this regard.
Various cytokines and cytokine antagonists (cDNA
encoding the human interleukin-1 receptor antagonist
(IL-1Ra) have also shown promising results as new
therapeutic agents for osteoporosis in animal models,
but their application is hindered by delivery problems.
However, there are some barriers on use of these drugs
for osteoporosis treatment that are as following [90, 91]:
– It was shown the calcified matrix of the bone tissue
is considered as the main barrier in gene therapy for
osteometabolic diseases, because the diffusion of the
vector through such a matrix is practically
impossible.
– Another obstacle in this regard is the use of single
therapeutic genes in most studies, as a single gene
cannot affect both the osteoblasts and the
osteoclasts at the same time.
Overall, some of these new drugs are including
frizzled-related protein inhibitor, glycogen synthase
kinase 3 (GSK-3) inhibitors; lithium, 603281-31-8, 6-
bromoindirubin-3´-oxime, AR28, matrix metalloprotein-
ases (MMPs), selective androgen receptor modulators
(SARMs), cell adhesion molecules (CAMs), L-carnitine
and its derivatives, amylin, adrenomedullin, reveromycin
A, insulin like growth factor-1 (IGF-1), and mesenchy-
mal stem cells [18, 49].
Combination therapy
It is hoped that the combination therapy show synergis-
tic and additive anti-osteoporotic effects. So, combined
agents with different mechanism of action such as anti-
resorptive plus anabolic agents or combination of two or
more agents with the same mode of action such as in-
hibitors of bone resorption can be considered as an
appropriate strategy for treatment of osteoporosis. How-
ever, it should be noticed that the metabolism of a drug
is varied individually, and the safety and efficacy of drugs
would change according to individual differences [92].
The combination of BPs and PTH 1-34 or PTH 1-84 in
several clinical trials resulted in reduction in anabolic
effect of PTH. In the most of studies alendronate in
combination with PTH was used. Although combination
therapy improved BMD at spine or hip, there was not
additional benefit on BMD compared with PTH therapy
alone [73]. The reduction of bone resorption markers
was found in the studies conducted on both sexes show-
ing no increase in bone formation markers in combin-
ation group. Recently, it was shown in one small clinical
trial in osteoporotic men that the combination of teripara-
tide and risendronate increased BMD at hip compared
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with either therapy alone. Although BPs plus PTH is not
recommended for management of osteoporosis,
immediate use of BPs after withdrawing teriparatide can
increase BMD at lumbosacral. Combinations of teripara-
tide and denosumab, estrogen or SERMs were shown
small additive effect on BMD [73, 93, 94]. However, it
should be noted that these studies were not designed to
assess the effect of the combination on fracture risk.
Although some studies reported the combination of
estrogen and BPs more effective than each of them
alone, this combination is not recommended, because of
the over suppression of bone turnover and enhancement
of fracture risk [95, 96]. Alendronate plus estrogen or
raloxifene increased BMD to a greater extent when com-
pared to either drug alone, in addition to unknown
benefit for fracture reduction [35, 57]. Overall, combin-
ation of the above drugs are not suggested because of
their small beneficial effect on BMD, no proven
additional benefit on fracture risk, increasing in cost and
potential adverse effects of the drugs [93].
Combination of anti-inflammatory agents such as anti-
tumor necrosis factor (anti-TNF) with anti-sclerostin anti-
bodies in animal models have been shown to be more
effective than either agent alone. By this combination was
observed prevention of cortical and trabecular bone loss,
and restoration of vertebral bone to levels in wild-type
mice who had not arthritis. In addition, significant reduc-
tion of osteoclast number, suppression of bone erosion to
lower level than baseline, and significant increase in thick-
ness, area, and proteoglycan content of cartilage were ob-
served [97]. Thus, it is suggested that medication selection
would be on an individual basis. Personalized medicine
that includes personalized genetic risk score and individu-
alized environmental exposure may have a key role in
pathophysiology of osteoporosis [98].
Osteoporosis in men
Due to the higher prevalence of osteoporosis among
women than men, greater focus is paid on treatment of
osteoporosis in women and several large randomized
clinical trials have been conducted on this population.
However, morality rate secondary to major fractures, es-
pecially of the hip, has increased in osteoporotic men
than in women. Thus special attention should be paid to
the treatment of osteoporosis in men. Similar approach
is recommended in treating osteoporosis in both sexes.
Osteoporotic men should intake adequate Ca (from
1000 to 1200 mg daily according to age) and vitamin D
(from 600 to 800 IU per day) supplementation in
addition to pharmacological or hormonal therapy. Be-
cause the most common cause of osteoporosis in men is
hypogonadism, testosterone replacement therapy can in-
crease BMD by 5% in spine. Data of clinical trials
confirms the beneficial effect of testosterone on BMD
for at least 2 years [99]. Androgens have beneficial ef-
fects on cardiovascular system and adverse effects on
prostate [100]. Androgen replacement therapy beside
other pharmacological agents for treatment of osteopor-
osis is recommended for hypogonadal men at fracture
risk [101]. Although it is expected that androgen therapy
should have beneficial effects in elderly men with osteo-
porosis, sarcopenia, or falls, a meta-analysis study did
not show its beneficial effects on bone health [102].
Overall, all pharmacological agents can be safely con-
sidered as a therapeutic option in the treatment of
osteoporosis in men [103]. Alendronate or risendronate
are favorable BPs that are recommended as the first line
pharmacological therapy for osteoporosis in men.
Zoledronic acid is a suitable alternative in patients who
do not tolerate oral BPs. Denosumab is a good choice in
osteoporotic men who are intolerant to other drugs or
have renal failure. BPs therapy should be stopped in men
with severe osteoporosis who are intolerant or unre-
sponsive to BPs therapy after one year, and PTH therapy
should be selected as an alternative. As recommended
for postmenopausal women, monitoring of treatment
with BMD evaluation is of utmost importance [101].
Recommendations for future research
It is not only required to conduct more studies on un-
derstanding the signaling pathway, but there are also
needs to conduct more studies on prevention of osteo-
porosis, safety and efficacy of anti-osteoporotic pharma-
cological agents, and drug discovery. It was reported in
most of the studies that antioxidative mechanism has
the main role in prevention and treatment of osteopor-
osis [104–106]. Some of these products include green
tea, quercetin, curcumin, phytoestrogens, omega-3 fatty
acids and soy isoflavones. In addition, it was reported
anti-resorptive effects for some active compounds such
as flavonoids, terpenoids, glycosides, lignans, coumarins,
alkaloids, and polyphenols, etc that have derived from
medical plants [107–111].
Polyphenols that are found in the most plants has
shown to be effective in increasing bone formation, de-
creasing bone resorption, and increasing bone strength.
Epigallocatechin-3-gallate (EGCG) is the main polyphe-
nol in green tea. Some of its beneficial effects on bone
health are modulated through suppression of the tran-
scription factors such as Runx2, or act through some
molecular signaling pathways such as OPG/RANKL,
mitogen-activated protein kinase (MAPK), and BMP that
resulted in suppression of osteoclast differentiation, and
affect osteoblast function [18]. Phytoestrogens can
inhibit aromatase and cytochrome P450 by binding to
estrogen receptors. High level of aromatase has positive
association with risk of breast, adrenal and prostate can-
cers. Other mechanisms include the influence on
Tabatabaei-Malazy et al. DARU Journal of Pharmaceutical Sciences  (2017) 25:2 Page 12 of 16
calcium absorption and its urinary excretion, prostaglan-
din synthesis, osteoblast formation and lipid oxidation.
The beneficial effect of phytoestrogens on bone resorp-
tion markers, and BMD in postmenopausal women in
some meta-analysis of randomized controlled trials was
reported, in contrast to others [112–115]. The effect of
isoflavones on fracture risk was not seen. However, it
should be noticed that phytoestrogens can be considered
as the best alternative of estrogen therapy for relief of
menopausal symptoms. Similar to synthetic drugs, it is
hypothesized that more beneficial effects for polyherbal
combination be revealed in the near future. The greens
+ TM a blend of several polyphenols including quercetin,
apigenin and luteolin, combination of several types of
omega-3 fatty acids, and Resveratrol in combination
with vitamin D have shown beneficial effects on bone
more than when used alone [18, 110, 116]. However,
most of these studies have been performed in vitro and
needs preclinical animal studies to optimize the dose
with maximum beneficial effects on bone health, and
then well-designed clinical studies with large sample
sizes and long follow-up duration in at-risk populations.
Conclusions
Currently, the development of pharmacological agents in
treatment of osteoporosis has discovered new agents that
effectively reduce fracture risk. Due to the lack of appro-
priate clinical trials for newer anabolic or antiresorptive
agents, until these agents are approved, it is recommended
to prescribe the current available agents that is more ap-
propriate to each patient. Thus, the physicians should be
aware about the current drugs and also newer agents’
mechanism of action, their beneficial effects on bone
health, the best time to prevent fractures, optimal benefi-
cial duration of treatment, and dosing requirement.
Some limitations exist despite the major advances in
drug discovery for treatment of osteoporosis. First, their
efficacy on hip fracture reduction is lower than what ob-
served on lumbosacral fracture. Secondly, potential ad-
verse events may emerge by using anti-osteoporotic
pharmacological agents in postmenopausal osteoporotic
women who need long term treatment. Thirdly; the ben-
efits associated with so called treatment strategies are
limited to selected patients, generally those at higher risk
of fracture. However, monitoring of complications in
long-term may raise some concerns. Forth, due to the
high cost of new agents, their usage should be restricted
in selective patients who are at high risk of fracture or
when failed response to first line treatment options. In
addition, individuality in the metabolism of a drug af-
fects drug safety and efficacy. On the other hand, the
progressive advances in the personalized therapy for
osteoporosis raises the necessity for identifying the main
genes and signaling pathways involved in bone loss of
individual patients. Henceforth, the effects of these genes
and pathways modulate the application of therapies in
every specific individual. Thus, personalized medicine
should be considered for genetic risk score and also for
environmental exposure assessment.
In addition to continuous attention to the early diag-
nosis of osteoporosis, more well-designed clinical trials
is required on the safety and efficacy of current available
anti-osteoporosis agents. As well, continuous preclinical
assessment of newer agents, conduction of clinical trials,
searching for novel approach in drug discovery based on
understanding of the pathophysiology of osteoporosis
are strictly recommend. The authors also suggest con-
ducting future research on plant-derived components as
the source of discovery of new agents, and also more
clinical trials with combination of two or more synthetic
drugs, plants, or drug-plant for treatment of osteopor-
osis as the solutions.
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IGF-1: insulin like growth factor-1; IOF: International Osteoporosis Foundation;
IU: international units; IV: intravenous; LIFT: Long-term Intervention on
Fractures with Tibolone; LOFT: Long-term Odanacatib Fracture Trial;
LRP5: LDL receptor-related protein5; MAPK: mitogen-activated protein kinase;
MMPs: matrix metalloproteinases; MORE: Multiple Outcomes of Raloxifene
Evaluation; NTX: N-telopeptide; PEPI: Postmenopausal Estrogen/Progestin
Intervention; PTHrP: PTH-related protein; RANK: receptor activator of NF-κB;
RANKL: RANK ligand; ROS: reactive oxygen species; Runx2: runt-related
transcription factor2; RUTH: Raloxifene Use for the Heart; SARMs: selective
androgen receptor modulators; SERMs: Selective estrogen receptor
modulators; SFRP: secreted frizzled-related protein; WHI: Women’s Health
Initiative; Wnt: wingless-type and integrase1
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